400 related articles for article (PubMed ID: 24467232)
1. Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy.
Barnidge DR; Dasari S; Botz CM; Murray DH; Snyder MR; Katzmann JA; Dispenzieri A; Murray DL
J Proteome Res; 2014 Mar; 13(3):1419-27. PubMed ID: 24467232
[TBL] [Abstract][Full Text] [Related]
2. Detecting monoclonal immunoglobulins in human serum using mass spectrometry.
Mills JR; Barnidge DR; Murray DL
Methods; 2015 Jun; 81():56-65. PubMed ID: 25916620
[TBL] [Abstract][Full Text] [Related]
3. Using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry to detect monoclonal immunoglobulin light chains in serum and urine.
Barnidge DR; Krick TP; Griffin TJ; Murray DL
Rapid Commun Mass Spectrom; 2015 Nov; 29(21):2057-60. PubMed ID: 26443406
[TBL] [Abstract][Full Text] [Related]
4. Direct Detection of Monoclonal Free Light Chains in Serum by Use of Immunoenrichment-Coupled MALDI-TOF Mass Spectrometry.
Sepiashvili L; Kohlhagen MC; Snyder MR; Willrich MAV; Mills JR; Dispenzieri A; Murray DL
Clin Chem; 2019 Aug; 65(8):1015-1022. PubMed ID: 31171529
[TBL] [Abstract][Full Text] [Related]
5. MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins.
Fatica EM; Martinez M; Ladwig PM; Murray JD; Kohlhagen MC; Kyle RA; Kourelis T; Lust JA; Snyder MR; Dispenzieri A; Murray DL; Willrich MAV
Clin Biochem; 2021 Nov; 97():67-73. PubMed ID: 34384797
[TBL] [Abstract][Full Text] [Related]
6. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic.
Milani P; Murray DL; Barnidge DR; Kohlhagen MC; Mills JR; Merlini G; Dasari S; Dispenzieri A
Am J Hematol; 2017 Aug; 92(8):772-779. PubMed ID: 28439985
[TBL] [Abstract][Full Text] [Related]
7. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
[TBL] [Abstract][Full Text] [Related]
8. IgG subclass distribution in patients with multiple myeloma or with monoclonal gammopathy of undetermined significance.
Papadea C; Reimer CB; Check IJ
Ann Clin Lab Sci; 1989; 19(1):27-37. PubMed ID: 2492788
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the analytical performance and the sensitivity of serum free light chains immunoassay in patients with monoclonal gammopathy.
Wolff F; Thiry C; Willems D
Clin Biochem; 2007 Mar; 40(5-6):351-4. PubMed ID: 17239359
[TBL] [Abstract][Full Text] [Related]
10. Analytical validation of the Hevylite assays for M-protein quantification.
Jacobs JFM; Haagen IA; Lodder A; van der Kroft C; de Kat Angelino CM; Croockewit S; Nieuwenhuys E; Gelderman KA
Clin Chem Lab Med; 2018 Jun; 56(7):1169-1175. PubMed ID: 29397379
[TBL] [Abstract][Full Text] [Related]
11. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report.
Murray DL; Puig N; Kristinsson S; Usmani SZ; Dispenzieri A; Bianchi G; Kumar S; Chng WJ; Hajek R; Paiva B; Waage A; Rajkumar SV; Durie B
Blood Cancer J; 2021 Feb; 11(2):24. PubMed ID: 33563895
[TBL] [Abstract][Full Text] [Related]
12. MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients.
Mellors PW; Dasari S; Kohlhagen MC; Kourelis T; Go RS; Muchtar E; Gertz MA; Kumar SK; Buadi FK; Willrich MAV; Lust JA; Kapoor P; Lacy MQ; Dingli D; Hwa Y; Fonder A; Hobbs M; Hayman S; Warsame R; Leung NR; Lin Y; Gonsalves W; Siddiqui M; Kyle RA; Rajkumar SV; Murray DL; Dispenzieri A
Blood Cancer J; 2021 Mar; 11(3):50. PubMed ID: 33664227
[TBL] [Abstract][Full Text] [Related]
13. Heavy/light chain assay in the monitoring of multiple myeloma.
Ting HY; Sthaneshwar P; Bee PC; Shanmugam H; Lim M
Pathology; 2019 Aug; 51(5):507-511. PubMed ID: 31253381
[TBL] [Abstract][Full Text] [Related]
14. Detection of kappa and lambda light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis.
Jaskowski TD; Litwin CM; Hill HR
Clin Vaccine Immunol; 2006 Feb; 13(2):277-80. PubMed ID: 16467338
[TBL] [Abstract][Full Text] [Related]
15. Phenotyping polyclonal kappa and lambda light chain molecular mass distributions in patient serum using mass spectrometry.
Barnidge DR; Dasari S; Ramirez-Alvarado M; Fontan A; Willrich MA; Tschumper RC; Jelinek DF; Snyder MR; Dispenzieri A; Katzmann JA; Murray DL
J Proteome Res; 2014 Nov; 13(11):5198-205. PubMed ID: 25134970
[TBL] [Abstract][Full Text] [Related]
16. Detection of serum M-protein in acetonitrile precipitates by MALDI-TOF mass spectrometry: A novel, low-cost methodology.
Mehra N; Gopisetty G; Subramani J; Dhanasekar S; Rajamanickam A; Perumal Kalaiyarasi J; Karunakaran P; Kannan K; Rajaraman S; Rajkumar T
Ann Clin Biochem; 2023 Sep; 60(5):339-348. PubMed ID: 37158306
[TBL] [Abstract][Full Text] [Related]
17. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
Dogaru M; Lazăr V; Coriu D
Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
[TBL] [Abstract][Full Text] [Related]
18. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
19. Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC-MS/MS.
Barnidge DR; Tschumper RC; Theis JD; Snyder MR; Jelinek DF; Katzmann JA; Dispenzieri A; Murray DL
J Proteome Res; 2014 Apr; 13(4):1905-10. PubMed ID: 24552626
[TBL] [Abstract][Full Text] [Related]
20. Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple Myeloma With Deep Responses.
Miyazaki K; Suzuki K
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):293-296. PubMed ID: 29472112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
